ERBB2 and neoplasm: Figure 7 shows the predicted time survival probabilities discriminating relatively lower- and higher-risk groups within each BRCA subtype in the above three types of survival time. When for a given risk group, KDM7A-DT expression is higher than the predicted cut-off value and the patients are assigned to the higher risk subgroup, then a role of KDM7A-DT is interpreted as ‘pro-oncogenic’, in the opposite case - as ‘tumor suppressor-like’ factor. The pro-oncogenic and tumor-suppression-like patterns were identified separately for luminal A, B, HER2+/ER- and (ER-/PR-/HER2-) Basal BRCA datasets.